Event-free and overall survival by cytogenetic subgroup of patients with Philadelphia-negative adult acute lymphoblastic leukemia on MRC UKALLXII/ECOG 2993
| Cytogenetic subgroup* . | Event-free survival . | Overall survival . | ||||
|---|---|---|---|---|---|---|
| 5 y, no. (95% CI) . | O/E† . | P† . | 5 y, no. (95% CI) . | O/E† . | P† . | |
| Total‡ | 38 (34-41) | 1.02 | .365 | 42 (38-45) | 1.02 | .458 |
| t(4;11)(q21;q23) | 24 (13-36) | 1.70 | < .001 | 24 (13-36) | 1.86 | < .001 |
| Other MLL/11q23 translocations | 29 (9-52) | 1.28 | .432 | 33 (12-56) | 1.26 | .462 |
| t(1;19)(q21;p13.3) | 29 (13-48) | 1.31 | .254 | 32 (14-51) | 1.26 | .342 |
| t(8;14)(q24.1;q32) | 13 (2-33) | 3.15 | < .001 | 13 (2-33) | 3.22 | < .001 |
| t(10;14)(q24;q11.2) | 34 (13-58) | 0.91 | .758 | 41 (17-64) | 0.86 | .652 |
| Other TCR translocations | 33 (14-55) | 1.24 | .458 | 33 (14-55) | 1.39 | .252 |
| 14q32 translocations | 33 (20-47) | 1.21 | .277 | 35 (22-49) | 1.18 | .366 |
| del(6q) | 29 (18-41) | 1.31 | .072 | 36 (23-48) | 1.26 | .145 |
| del(7p) | 22 (8-40) | 1.27 | .306 | 26 (11-45) | 1.41 | .137 |
| −7§ | 36 (16-57) | 1.15 | .617 | 36 (16-57) | 1.32 | .328 |
| +8§ | 22 (8-40) | 1.45 | .108 | 22 (8-40) | 1.50 | .078 |
| +X§ | 24 (11-40) | 1.22 | .300 | 27 (13-44) | 1.38 | .096 |
| del(9p) | 49 (37-60) | 0.73 | .043 | 58 (46-69) | 0.70 | .032 |
| Abnormality of 11q | 40 (22-57) | 0.99 | .964 | 48 (29-65) | 0.96 | .858 |
| del(12p) | 34 (18-51) | 1.05 | .844 | 41 (24-58) | 0.98 | .933 |
| del(13q)/−13 | 32 (19-47) | 1.09 | .650 | 41 (26-56) | 1.07 | .731 |
| del(17p) | 32 (18-46) | 1.08 | .681 | 36 (21-51) | 1.12 | .547 |
| Complex karyotype | 21 (10-35) | 1.57 | .009 | 28 (15-43) | 1.48 | .027 |
| Low hypodiploidy/near triploidy | 18 (7-34) | 1.78 | .003 | 22 (9-38) | 1.86 | .001 |
| High hyperdiploidy | 50 (38-60) | 0.67 | .007 | 53 (41-64) | 0.69 | .015 |
| Tetraploidy | 46 (20-68) | 0.71 | .335 | 65 (35-84) | 0.58 | .170 |
| Other abnormality‖ | 38 (28-48) | 0.96 | .727 | 39 (29-49) | 0.96 | .731 |
| Normal karyotype | 43 (36-50) | 0.86 | .064 | 48 (40-55) | 0.83 | .025 |
| Cytogenetic subgroup* . | Event-free survival . | Overall survival . | ||||
|---|---|---|---|---|---|---|
| 5 y, no. (95% CI) . | O/E† . | P† . | 5 y, no. (95% CI) . | O/E† . | P† . | |
| Total‡ | 38 (34-41) | 1.02 | .365 | 42 (38-45) | 1.02 | .458 |
| t(4;11)(q21;q23) | 24 (13-36) | 1.70 | < .001 | 24 (13-36) | 1.86 | < .001 |
| Other MLL/11q23 translocations | 29 (9-52) | 1.28 | .432 | 33 (12-56) | 1.26 | .462 |
| t(1;19)(q21;p13.3) | 29 (13-48) | 1.31 | .254 | 32 (14-51) | 1.26 | .342 |
| t(8;14)(q24.1;q32) | 13 (2-33) | 3.15 | < .001 | 13 (2-33) | 3.22 | < .001 |
| t(10;14)(q24;q11.2) | 34 (13-58) | 0.91 | .758 | 41 (17-64) | 0.86 | .652 |
| Other TCR translocations | 33 (14-55) | 1.24 | .458 | 33 (14-55) | 1.39 | .252 |
| 14q32 translocations | 33 (20-47) | 1.21 | .277 | 35 (22-49) | 1.18 | .366 |
| del(6q) | 29 (18-41) | 1.31 | .072 | 36 (23-48) | 1.26 | .145 |
| del(7p) | 22 (8-40) | 1.27 | .306 | 26 (11-45) | 1.41 | .137 |
| −7§ | 36 (16-57) | 1.15 | .617 | 36 (16-57) | 1.32 | .328 |
| +8§ | 22 (8-40) | 1.45 | .108 | 22 (8-40) | 1.50 | .078 |
| +X§ | 24 (11-40) | 1.22 | .300 | 27 (13-44) | 1.38 | .096 |
| del(9p) | 49 (37-60) | 0.73 | .043 | 58 (46-69) | 0.70 | .032 |
| Abnormality of 11q | 40 (22-57) | 0.99 | .964 | 48 (29-65) | 0.96 | .858 |
| del(12p) | 34 (18-51) | 1.05 | .844 | 41 (24-58) | 0.98 | .933 |
| del(13q)/−13 | 32 (19-47) | 1.09 | .650 | 41 (26-56) | 1.07 | .731 |
| del(17p) | 32 (18-46) | 1.08 | .681 | 36 (21-51) | 1.12 | .547 |
| Complex karyotype | 21 (10-35) | 1.57 | .009 | 28 (15-43) | 1.48 | .027 |
| Low hypodiploidy/near triploidy | 18 (7-34) | 1.78 | .003 | 22 (9-38) | 1.86 | .001 |
| High hyperdiploidy | 50 (38-60) | 0.67 | .007 | 53 (41-64) | 0.69 | .015 |
| Tetraploidy | 46 (20-68) | 0.71 | .335 | 65 (35-84) | 0.58 | .170 |
| Other abnormality‖ | 38 (28-48) | 0.96 | .727 | 39 (29-49) | 0.96 | .731 |
| Normal karyotype | 43 (36-50) | 0.86 | .064 | 48 (40-55) | 0.83 | .025 |
O/E indicates observed-to-expected events ratio from the log-rank test.
See “Patients, materials, and methods” for a full definition of the individual cytogenetic subgroups.
Observed-to-expected ratios and P value derived from the log-rank test comparing the outcome of each cytogenetic group to all other Philadelphia-negative patients with a successful cytogenetic result, except for the total group which was compared with patients with a failed cytogenetic result or without cytogenetics.
Philadelphia-negative cases with a successful cytogenetic result.
These groups exclude cases with low hypodiploid/near triploidy, high hyperdiploidy, and tetraploidy.
Abnormal karyotypes, excluding those with any of the above abnormalities.